Original Article: Daraxonrasib or Chemotherapy in Previously Treated Metastatic Pancreatic Cancer (phase 3 RASolute 302 trial) nej.md/4nWaxvM
#ASCO26 | @ASCO

ALT A two-panel line graph shows overall survival in two populations, comparing darovasertib (blue line) and chemotherapy (gray line) treatments. Panel A depicts the RAS G12 population, while Panel B shows the overall population. Hazard ratios and confidence intervals are detailed in each panel.

ALT This image shows two line graphs titled "Progression-free Survival in the RAS G12 Population" and "Progression-free Survival in the Overall Population." Both graphs compare survival rates over 13 months between two groups: one receiving darovasertib and the other receiving chemotherapy. Accompanying the graphs are tables detailing the number of events and patients at risk for each treatment group.
Warapen Treekit retweeted
Cheers, chills, and a standing ovation when RASolute 302 showed unprecedented survival on daraxonrasib for patients with progressive pancreatic cancer
Seldom do you sense you’re witnessing a historic moment in cancer care but this feels like ras targeting has arrived
#ASCO26
Warapen Treekit retweeted
#PancreaticCancer remains a challenge. Targeting #KRAS was a key step—but responses are often temporary. New @theNCI-supported work identifies a protein that may drive resistance, opening a path to extend treatment benefit in pancreatic and other cancers go.nih.gov/yRVSjjZ
Proud to share our @NaturePortfolio research article: "RASH3D19 as a mediator of RAS pathway activation through a positive feedback loop in KRAS-mutant cancer", now out in Nature Cell Biology.
Read it here: nature.com/articles/s41556-0…
mdanderson.org/newsroom/rese…
2
35
Warapen Treekit retweeted
Congratulations to Subrata Sen & team
@MDAndersonNews for their @NatureCellBio paper:
RASH3D19 mediates RAS activation through a positive feedback loop in KRAS-mutant cancer
nature.com/articles/s41556-0…
Warapen Treekit retweeted
In this @BrJCancer study, scientists from @MDAndersonNews discover that epigenetic activation of 🧦 SOX11 drives 🚙 recurrence of ductal carcinoma in-situ (DCIS) and progression 📈 to invasive cancer.
😎 Check it out: go.nature.com/3VbMKew
Warapen Treekit retweeted
Examining the role of eEF1A2 in cancer, researchers at @MDAndersonNews find the factor normally interacts with the tumor suppressor #PTEN to repress the #CellCycle and degrade Aurora-A, but that the latter is more abundant in #BreastCancer tissues. scim.ag/67G
Warapen Treekit retweeted
The most important paper of 2024 🤯
Excited to share @AllofUsResearch program’s flagship genomics paper describing 245,388 clinical-grade genome sequences encompassing >1 billion genetic variants published today in @Nature
nature.com/articles/s41586-0…
Warapen Treekit retweeted
A riddle for scientists: what is (1) better than publishing in Nature, (2) more evil than reviewer 2, (3) the postdocs have it, (4) the Nobel prize winners need it, and (5) if you publish it you perish?
Warapen Treekit retweeted
Calling all coffee enthusiasts! Exciting research reveals how caffeine influences #intestinal tumor initiation. Interested in learning more? Click the link ➡️ ow.ly/RisN50PQgYH
Warapen Treekit retweeted
Fascinating talk from @HansClevers on identifying pks E. Coli mutational signatures in intestinal organoid cultures. Elegant work and beautiful animations alongside. #AACR22
Warapen Treekit retweeted
Cytotoxic CD4+ T cells in cancer: Expanding the immune effector toolbox dlvr.it/SFgDwD
Augmented lipocalin-2 is a molecular feature of COPD-associated LUAD and counteracts LUAD development by maintaining anti-tumor immunity.
atsjournals.org/doi/abs/10.1…
#lungcancer #COPD #EndCancer
@humam_kadara @AnsamSinjab
7






















